Compass Therapeutics is a biotechnology company dedicated to developing innovative therapies for cancer and other serious diseases
The company focuses on harnessing the power of the immune system to create novel treatment options that target specific pathways involved in tumor growth and immune response. By employing a combination of advanced technologies and comprehensive research, Compass Therapeutics aims to deliver transformative medicines that improve patient outcomes and address unmet medical needs in oncology. Their pipeline includes a range of therapeutic candidates that are designed to enhance the immune system's ability to fight cancer effectively.
Momentum investors seek to take advantage of share price rallies to buy companies before they peak; analysts think these three firms still have room to grow.
Gainers Baudax Bio, Inc. (NASDAQBXRX) shares surged 59.7% to $5.03 after the company announced the outcome of its first interim analysis in a Phase II trial of BX1000 for neuromuscular blockade in patients undergoing elective surgery.
